Cancer Care of Western North Carolina

Head and Neck Cancer News

Targeted radiotherapy for head and neck cancer could reduce the risk of dry mouth (February 22, 2017)

A troublesome side effect of radiation therapy treatment of cancers involving the head and neck is dry mouth.  This occurs as a consequence of radiation damage to the salivary glands.  According to a new study, changing the intensity of radiotherapy... Continue Reading

Nearly half of U.S. men actively infected with HPV, study finds HPV-linked cancers on the rise in men, but nearly 9 in 10 vaccine-eligible men are unvaccinated! (February 20, 2017)

By Rachel Tompa / Fred Hutch News Service The most common sexually transmitted infection in the U.S. has a bit of a twist. It’s what’s known as a “subclinical infection” — those infected suffer no immediate consequences, but years later have... Continue Reading

Twice-daily radiation therapy reduces mortality from head and neck cancer (February 14, 2017)

Treating head and neck cancer patients with a twice-daily radiation therapy schedule combined with chemotherapy could save more lives, according to new research presented at the European Cancer Congress 2017.1 Around 600,000 people are diagnosed with... Continue Reading

Opdivo Approved for Advanced Head and Neck Cancer (November 28, 2016)

The United States Food and Drug Administration (FDA) has approved the immunotherapeutic agent, Opdivo® (nivolumab) for the treatment of advanced head and neck cancer. Specifically,  the indication is for the treatment of squamous cell carcinoma of the... Continue Reading

PET/CT Combined More Effective Than MRI in Monitoring Head and Neck Cancer Patients’ Response to Treatment (October 5, 2016)

According to a recent study, combining PET/CT to monitor response to treatment in head and neck cancer patients appears more effective than MRI. Using PET/CT may better inform doctors whether treatment for head and neck cancer is working after just one... Continue Reading

Keytruda® Approved for Advanced Head and Neck Cancer (September 7, 2016)

The United States Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab) for the treatment of advanced head and neck cancer that has stopped responding to platinum-based chemotherapy agents.1 Globally, head and neck cancer comprises... Continue Reading

Compliance with Radiation Schedules Improves Survival in Head and Neck Cancer (June 9, 2016)

Patients with head and neck cancer who comply with their scheduled radiation treatments have significantly improved outcomes compared to those who miss 2 or more of their appointments within the prescribed time period. These results were recently published... Continue Reading

Long-Lasting Responses Achieved with Keytruda® in Advanced Head and Neck Cancer (June 8, 2016)

Treatment with the immune-stimulating agent, Keytruda® (pembrolizumab), provides impressive long-term outcomes for some patients with metastatic or recurrent head and neck cancer. These results were recently presented at the 2016 annual meeting of the... Continue Reading

Follow-Up Scans Reduce Need for Some Invasive Surgeries in Head and Neck Cancer (June 6, 2016)

Utilizing PET-CT scans following treatment for patients with head and neck cancer that has spread to their lymph nodes significantly reduces the need for invasive follow-up surgery. These results were recently published in the New England Journal of Medicine. Patients... Continue Reading

More Evidence that PD-1 Inhibitors Improve Survival in Head and Neck Cancer (May 25, 2016)

Results from a recent large trial indicate that treatment with the immunotherapy agent Opdivo® (nivolumab) nearly doubles the survival rate at one year in patients with advanced head and neck squamous cell carcinoma. These results prompted the United... Continue Reading

Latest Head and Neck Cancer News By Stage


General Head and Neck Cancer

Twice-daily radiation therapy reduces mortality from head and neck cancer (February 14, 2017)

Treating head and neck cancer patients with a twice-daily radiation therapy schedule combined with chemotherapy could save more lives, according to new research presented at the European Cancer Congress 2017.1 Around 600,000 people are diagnosed with... Continue Reading

Opdivo Approved for Advanced Head and Neck Cancer (November 28, 2016)

The United States Food and Drug Administration (FDA) has approved the immunotherapeutic agent, Opdivo® (nivolumab) for the treatment of advanced head and neck cancer. Specifically,  the indication is for the treatment of squamous cell carcinoma of the... Continue Reading

PET/CT Combined More Effective Than MRI in Monitoring Head and Neck Cancer Patients’ Response to Treatment (October 5, 2016)

According to a recent study, combining PET/CT to monitor response to treatment in head and neck cancer patients appears more effective than MRI. Using PET/CT may better inform doctors whether treatment for head and neck cancer is working after just one... Continue Reading

Keytruda® Approved for Advanced Head and Neck Cancer (September 7, 2016)

The United States Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab) for the treatment of advanced head and neck cancer that has stopped responding to platinum-based chemotherapy agents.1 Globally, head and neck cancer comprises... Continue Reading

Compliance with Radiation Schedules Improves Survival in Head and Neck Cancer (June 9, 2016)

Patients with head and neck cancer who comply with their scheduled radiation treatments have significantly improved outcomes compared to those who miss 2 or more of their appointments within the prescribed time period. These results were recently published... Continue Reading

More General Head and Neck Cancer